Background: Lithium is the mainstay of treatment for bipolar disorder, mania and an augmentation therapy in patients with treatment resistant depression. It has a narrow therapeutic index, with recognized adverse multi-system and endocrine side effects. Aim: To assess the impact of lithium therapy, in particular lithium toxicity, on the development of endocrine and renal disorders in a cohort of patients in a single tertiary referral centre in Ireland. Study design: A retrospective analysis was performed of the prevalence of lithium toxicity and renal, thyroid and parathyroid dysfunction in our study population. Methods: We collected laboratory data from the Clinical Chemistry department of the Adelaide and Meath Hospital incorporating the National Children's Hospital (AMNCH), Dublin, Ireland. Our study population included all patients who had at least one serum lithium measurement from January 1st 2000 to December 31st 2014 inclusive. Results: A total of 580 patients were included in the study. Among our study group, 70 patients (12.1%) had 1 toxic lithium measurement (lithium level >1.2 mmol/l). 27.8% (n > 161) of patients developed stage 3 Chronic kidney Disease (CKD) or higher, which was commoner in those patients who developed toxic lithium levels (P < 0.0001) and in those who developed hypernatraemia (P > 0.0001). 16.2% of patients (n > 94) had one serum sodium >145 mmol/l during follow up. 60 patients (10.3%) had a TSH >10 mU/l, while complete suppression of TSH (<0.05 mU/l) was observed in 22 patients (3.8%) during follow-up. 4% (n > 37) of the study population had !1 serum corrected calcium level > 2.55 mmol/l, and 4 patients had biochemical confirmation of primary hyperparathyroidism but PTH levels were only performed in 2.8% (n > 16) of the study population. Conclusion: Stage 3 CKD is common in patients receiving lithium therapy. Lithium toxicity is associated with CKD and hypernatraemia. Thyroid dysfunction and hypercalcaemia are common in patients receiving lithium therapy. Patients receiving lithium therapy require surveillance of renal, thyroid and bone biochemistry.
Introduction
Lithium is widely used in the treatment of patients with bipolar disorder, particularly for acute mania and relapse prevention. Lithium has also been shown to be an effective treatment for reducing the risk of suicide in people with mood disorders 1 and is a treatment for resistant depression. Lithium toxicity can occur at doses close to therapeutic levels. Early detection of toxicity is achieved by careful monitoring of patients and close collaboration between psychiatrists and physicians. Lithium therapy is associated with endocrine and metabolic disturbances, particularly involving the kidney, thyroid and parathyroid glands. McKnight et al addressed the toxicity profile of lithium therapy in a recent meta-analysis and showed an associated reduction in urinary concentrating ability by 15% of normal maximum; however the absolute risk of renal failure was low. 2 The studies analyzed in this meta-analysis included patients on lithium therapy dating back to 1987, when recommended lithium levels were higher. However, Aiff et al showed that the risk of CKD could not be eliminated by adherence to modern treatment principles. 3 Other recent observational studies support the evidence that chronic lithium use is associated with an increased risk of renal impairment. 4, 5 Shine et al. 6 reported an increased risk of at least stage 3 chronic kidney disease (HR 1.93; P < 0.0001) and a recent population based cohort study contradicted the idea that long-term lithium therapy is associated with nephrotoxicity in the absence of episodes of acute intoxication. 7 Lithium treatment is also associated with thyroid disorders (hypothyroidism and less frequently hyperthyroidism), hyperparathyroidism and nephrogenic diabetes insipidus. Shine et al performed a large retrospective analysis investigating the incidence of renal, thyroid, and parathyroid dysfunction associated with lithium use. 6 Their analysis suggested that patients receiving lithium
were at a higher risk of hypothyroidism (HR 2.31; P < 0.0001) and raised serum calcium concentration (HR 1.43; P < 0.0001).
The recently updated National Institute for Health and Care Excellence (NICE) guidelines for the management of bipolar disease, 8 have now incorporated the routine surveillance of serum calcium in addition to renal profile and thyroid function, which is not present in the Irish Medicines Safety Network (IMSN) best practice guidelines for prescribing and monitoring of lithium therapy published in 2012. 9 Given the discrepancy between these guidelines and the differing results in recent publications, the aims of our study were to assess the impact of lithium therapy and in particular lithium toxicity on the development of endocrine and renal disorders and to assess surveillance rates for these abnormalities in a single tertiary referral centre in Ireland.
Materials and methods

Study design and cohort
In a tertiary referral centre, a retrospective cohort study of all patients on lithium therapy from January 1, 2000 to December 31, 2014 inclusive was performed. Patients were identified in collaboration with the hospital Psychiatry Department and by analysing the Clinical Chemistry laboratory system for serum lithium measurements. The study cohort included all patients in the laboratory system with at least one serum lithium measurement during the study period.
Ethical approval
Ethical approval for the study was sought and approved by the Tallaght Hospital/St. James's Hospital Joint Research Ethics
Committee. All patient information studied was anonymized. It was a non-sponsored study and the clinical management of patients was not altered during the study period.
Data collection and definitions
Using the Clinical Chemistry database, routinely collected data for each patient were extracted. This included serum lithium levels, parathyroid, thyroid, renal and metabolic profiles performed on each patient over the 14-year period. The date of the earliest serum lithium level was defined as the initiation of therapy as we did not perform a clinical chart review. The numbers of lithium measurements during follow-up, peak lithium levels, and the number of toxic lithium levels for each patient were recorded. The definition of lithium toxicity can differ depending on treatment aims for each individual patient. We did not have clinical information regarding the primary psychiatric diagnosis or clinical signs and symptoms to suggest toxicity, and so we defined lithium toxicity for the purposes of this study as a serum lithium concentration >1.2 mmol/l, based on the NICE guidelines for management of Bipolar disorder in adults, 8 however it is acknowledged that patients may develop toxicity at lower levels. Hypernatraemia was defined as a serum sodium concentration >145 mmol/l and hyponatraemia as a serum sodium concentration <135 mmol/l. We recorded all serum sodium concentrations >145 mmol/l and this was used as a crude surveillance method to identify patients with possible nephrogenic diabetes insipidus, with the understanding that this would highlight only a subset of patients who developed dehydration and hypernatraemia whereas the majority of patients with nephrogenic diabetes insipidus remain eunatraemic due to intact thirst mechanisms. We recorded paired serum and urine osmolality measurements when available.
Through the hospital laboratory database, we were able to identify the number of hospitalizations for each patient over the 14-year study period and the hospital service under which they were admitted. We were also able to assess whether the patient developed hypernatraemia as an inpatient or in the outpatient setting. We recorded the number of elevated creatinine levels for each patient, based on the laboratory reference range for sex and age, measured in lmol/l and eGFR was calculated using the MDRD equation. We classified the renal profile of our study population based on their estimated glomerular filtration rate (eGFR) using the Kidney Disease Outcome Qualitive Initiative (KDOQI) stages of chronic kidney disease (CKD); Stage 1 (>90 ml/min/1. ). Hyperthyroidism was defined as a suppressed thyroid stimulating hormone 1 concentration <0.3mU/l and hypothyroidism was defined as a TSH concentration >4.2mU/l. All available thyroid peroxidase antibodies (TPO antibodies) were recorded for each patient during the follow up period. We did not record whether patients were on thyroxine replacement at the time of laboratory testing. All measured serum calcium levels were adjusted for albumin concentration. Hypocalcaemia was defined as a corrected serum calcium concentration <2.15 mmol/l. Hypercalcaemia was defined as a corrected serum calcium concentration >2.55 mmol/l. All available parathyroid hormone levels were recorded for each patient. Elevated PTH was defined as a PTH result above the upper reference of the assay in use at the time.
Statistical analysis
SPSS version 22 was used for statistical analysis. A significance level of P < 0Á05 was used, and we did not adjust for multiple comparisons. Data are expressed in median and interquartile range unless otherwise stated. Estimated GFR was calculated using the abbreviated MDRD equation, as per the UKCKD guideline. Chi-square (and fisher exact) analysis was used to identify significant observations between subgroups of the population.
Results
Demographics
A total of 580 patients were included in the study cohort ( Table 1 ). The median age of the study population was 55 years (IQR 44-65). 42% (n ¼ 337) were female and 58% (n ¼ 243) were male. The median duration of follow-up was 9 years (IQR 3-13). Within our study population, the overall median number of lithium measurements per patient per annum was 1 (IQR 0.44-1.5). Figure 1A depicts the distribution of frequency of lithium measurements during follow up across the study population.
The median number of hospitalizations per patient over the 14-year study period was 2 (IQR 0-5). The maximum number of hospitalizations per patient was 82. 149 patients (25.7%) had hospital admissions under medical teams only, 116 patients (20%) were only admitted under the psychiatric services. 139 patients (24%) had hospital admissions under both general medical and psychiatric services during the study period.
Lithium toxicity
The median peak lithium level per patient was 0.82 mmol/l (IQR 0.63-1.04). Among our study group, 70 patients (12.1%) had !1 toxic lithium measurement (>1.2 mmol/l) over the study period. Figure 1B depicts the distribution of frequency of toxic lithium measurements in the study population. 39 patients had toxic lithium levels recorded as an inpatient. Of these, 17 patients had toxic lithium levels under the general medical service, 23 patients had toxic lithium levels during an admission under the psychiatry team, including 1 patient who had toxic lithium levels during both medical and psychiatric admissions over the study period. As we did not perform a clinical chart review, we do not know whether lithium toxicity prompted hospitalization.
We compared the frequency of endocrine and renal abnormalities observed in the patient group who developed lithium toxicity, with those patients who had no toxic lithium levels during follow-up (Table 1) . 51.4% (n ¼ 36) of the patient group with toxic lithium levels had an eGFR <60 ml/min/1.73m 2 , as compared to 24.5% (n ¼ 125) of the patient group with no toxic lithium levels (P < 0.0001). There was a significant negative correlation observed between median peak lithium levels and eGFR (r-0.2535; P < 0.0001) (Figure 2A ). Hypernatraemia (40% vs.17.5%; P ¼ 0.0003), hypercalcaemia (15.7% vs. 5.1%; P ¼ 0.0024) and hypothyroidism (44.3% vs. 28.8%) were more prevalent in the patient group who had toxic lithium levels as compared to patients who did not have a toxic lithium level during follow-up.
Renal impairment and nephrogenic DI
Our analysis revealed that 27.8% (n ¼ 161) of the study population had an eGFR <60 ml/min/1.73m 2 , consistent with stage 3 CKD or worse. Figure 2B shows the distribution of the study population based on their stage of CKD. In total, 16.2% of patients (n ¼ 94) had at least one serum sodium > 145 mmol/l during follow up. Of these 94 patients, 33 patients had hypernatraemia recorded during a hospital admission, while in 61 patients; hypernatraemia was recorded in the outpatient setting. 29 patients had evidence of hypernatraemia during a medical hospital admission, while 20 patients had hypernatraemia recorded during admission under the psychiatry service. However, there was a higher number of serum sodium measurements per patient per year among those admitted under the medical teams compared to those admitted under the psychiatry service (mean 4.58/patient/year vs. 2.859/patient/year; P ¼ 0.0162).
Among the 94 patients who had >1 serum sodium > 145 mmol/l during follow-up, we found that 44.2% (n ¼ 42) had an eGFR < 60 ml/ min/1.73m 2 ( Figure 3 ). 29 patients (30.5% of patients with evidence of hypernatraemia during follow-up were investigated further with paired serum and urine osmolality samples. 12 of these 29 patients (41.4%) with hypernatraemia had an inappropriately low urine osmolality for the degree of plasma hyperosmolality.
Thyroid hormone dysfunction
Thyroid function tests were measured at least once in 97% (n ¼ 560) of the study population (Table 2) . Of these, abnormalities of thyroid stimulating hormone 1 were detected in 232 patients, representing 40% of the study population. 178 (30.7%) patients had an elevated TSH (>4.2mU/l), and 60 (10.3%) patients had a TSH > 10mU/l. A suppressed TSH (<0.3mU/l) was observed in 54 (9.3%) patients, and complete suppression (TSH < 0.05mU/l) was observed in 22 patients (3.8%). Thyroid peroxidase antibodies (TPO antibodies) were available in 71 (12.2%) patients within our study and 35 patients (49.3%) had positive TPO antibodies. One third (n ¼ 19) of patients with a TSH > 10mU/l had positive TPO antibodies, however, they were Calcium homeostasis and parathyroid hormone action 503 (86.7%) patients had at least one serum calcium measurement during the follow-up period. Hypocalcaemia (corrected for albumin) was observed in 21 (3.6%) patients. 6.4% (n ¼ 37) of the study population had one or more serum corrected calcium level >2.55 mmol/l. 16 (2.8%) patients had a parathyroid hormone level available on the laboratory system and 25% (n ¼ 4) of these had confirmed biochemical evidence of primary hyperparathyroidism.
Discussion
We have shown that chronic kidney disease, electrolyte abnormalities and endocrinopathies are common in patients who receive lithium and that patients who develop lithium toxicity develop these abnormalities more frequently. Current NICE guidelines for the management of bipolar disease, 8 that are adopted by the Royal College of Psychiatrists, recommend measuring plasma lithium levels every 6 months in a stable patient and every three months for higher risk patients, such as older patients, those taking drugs that interact with lithium, patients with poorer compliance and whose last plasma lithium level was !0.8 mmol/l. Among our study group, the median number of lithium measurements per year during follow-up was 1 (IQR 0.44-1.5) with a median follow-up per patient of 9 years (IQR 3-13). This most likely reflects the historic nature of our study duration with assessments from 2000 to 2014. In recent years, there has been a greater emphasis on systematic monitoring for adverse effects in patients receiving lithium. Also, as we did not perform a clinical chart review we did not determine whether lithium therapy had been withdrawn or discontinued at any point during the follow-up period. If this had been the case then no further assessment of lithium levels would have been required during follow up, which would impact on the number of lithium levels per annum. When assessing the impact of lithium on renal function it is important to differentiate whether the data relates to the impact of lithium administration or to the impact of lithium toxicity. Our study revealed that 27% (n ¼ 157) of patients had evidence of stage 3 CKD (or worse) during the 14-year follow-up. The first formal meta-analysis by Knight et al discussed in detail the effects of long-term lithium on renal function, 2 and concluded that there was little evidence for a clinically significant reduction in renal function in most patients, and the risk of end stage renal failure is low. However, limitations of this metaanalysis included the exclusion (in many studies) of patients with a history of lithium toxicity and provision of insuffiicent information to separate out these individuals or link the clinical presentations to number of episodes of toxicity. A recent large retrospective cohort study by Shine et al. 6 reported that the presence of lithium toxicity was significantly associated with stage 3 CKD. The pathophysiology of chronic lithium induced renal impairment appears to be a chronic tubulointerstitial nephropathy. 15, 16 The degree of interstitial fibrosis on renal biopsy has been reported to be related to the duration and cumulative dose of lithium. 17 One study reports patients with chronic lithium exposure for more than 18 years may have an irreversible defect.
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This may also be the result of confounding effects of secondary glomerulosclerosis from diabetes and cardiovascular disease, as these disorders are also increased in patients with bipolar disease compared with the general population. 19 While monitoring of renal function is imperative in patients receiving lithium therapy, in clinical practice this may be lacking. A large French study showed that serum creatinine levels had not been performed in 40% of patients on lithium over the 7-year period of 1997-2004. 20 In contrast, 100% of our study population had serum creatinine levels measured. A recent population-based cohort study of 1120 patients with a mean duration of exposure to lithium of 55 months (SD 42) suggested no effect of stable lithium therapy (lithium levels within the therapeutic range) on the rate of change of eGFR over time. 7 We observed a higher prevalence of renal impairment in the patient group who developed toxic lithium levels (51.4%) than in those patients with lithium levels in the normal range throughout follow up (24.5%; P < 0.0001).
Another potential renal side effect of lithium therapy is nephrogenic diabetes insipidus (NDI), 10 which is characterized by the kidneys inability to concentrate urine, due to renal resistance to vasopressin, causing a clinical polyuric syndrome. The molecular mechanism of lithium related urinary concentration defect involves a dysregulation of the aquaporin system in principal cells of the collecting duct. Nephrogenic DI associated with lithium use is often reversible after the withdrawal of the drug, particularly with reversal of hypovolaemia. However, it can take several months or years for full re-establishment of the renal ability to concentrate urine in some cases. 14 Reversibility is often not achieved in the presence of associated nephritis. Up to 40% of patients on long-term lithium therapy may develop nephrogenic DI. 11 In the majority of patients with Diabetes Insipidus eunatraemia is maintained by an intact thirst mechanism. In total, 16.2% of our patients had at least one serum sodium > 145 mmol/l, with significantly higher rates in patients with CKD. While this is not definitive evidence of NDI, and few of our patients had detailed assessment to allow us diagnose NDI with certainty, it is probable that hypernatraemia in this group may well reflect NDI. We have shown previously in a large cohort of patients with central DI 12 (CDI) that 12.1% developed hypernatraemia during follow up of 7 years (IQR 3.5-12) 13 with the majority of these episodes occurring while the patient was hospitalized. Hypernatraemia appears to be higher in patients on lithium therapy than in patients with diagnosed central DI, which may be related to impaired conscious level secondary to antipsychotic medication or a primary thirst problem affecting their consumption of free water. Only one third (n ¼ 32) of our study population with hypernatraemia had urine osmolality performed, of which 12 patients (37.5%) had inappropriately low urine osmolality with a paired elevated serum osmolality. While recent publications have focused on the risk of renal impairment in patients receiving lithium therapy, less emphasis has been placed on the association with other metabolic and endocrine disturbances. In addition to recording renal outcomes in our study population, we also analyzed the prevalence of alterations in calcium and thyroid homeostasis. Lithium has many actions on thyroid physiology and is known to cause goitre, hypothyroidism and be associated with both thyroid autoimmunity and hyperthyroidism. 21 An important thyroidal action of lithium is to inhibit thyroid hormone release, 23 in both euthyroid and hyperthyroid patients. There is no evidence that stopping lithium will lead to normalization of thyroid function in this group. The immunological influence of lithium on thyroid antibody concentrations can lead to a more rapid onset of thyroid autoimmunity. Some degree of hypothyroidism was confirmed in approximately 20% of our study population. We did not record patient medication and so the prevalence of thyroid dysfunction, may be an underestimate if we consider the normalization of TSH in patients with hypothyroidism taking appropriate thyroxine replacement. The prevalence of hypothyroidism in lithium treated patients in the literature ranges from 6 to 50%. 21, 22 Primary hyperparathyroidism was confirmed in only 4 patients (0.7%), however hypercalcaemia was observed in 6% (n ¼ 37) of the total study population. The mechanism of action of lithium-induced hyperparathyroidism is thought to be attributable to the inactivation of the calcium sensing receptor and interference with intracellular second messenger signalling reulting in a shift in the set-point of the calcium-PTH curve to the right with decreased parathyroid gland sensitivity to serum calcium level. 30 The data on the effects of lithium on parathyroid hormone (PTH) and serum calcium levels are conflicting.
Cross-sectional studies of lithium-associated hypercalcaemia and hyperparathyroidism report elevated PTH and/or serum calcium above the normal reference rane in 12-25% of patients. [24] [25] [26] Within the general population prevalence estimates of primary hyperparathyroidism are of one to seven cases per 1000 adults. 27, 28 Most patients with lithium-induced hypercalcaemia have mild asymptomatic hypercalcemia and the long-term consequences are unknown. 29 There have been conflicting results regarding the impact of lithium of calcium metabolism that is likely secondary to the heterogeneous nature of the studies analysed. [31] [32] [33] The main strength of our study was the large study population of 580 patients and the duration of follow-up of 14 years. The main limitations include a retrospective bias; a heterogeneous study population; and lack of clinical information of patient medical history, concomitant medication or presentation. We did not perform a chart review and so we had to assume that patients were on long-term maintenance lithium therapy rather than staggered therapy.
Considering all these aspects related to the use of lithium, it is important to be aware of and familiar with all potential endocrine and renal abnormalities that require monitoring in patients using this medication. Withdrawal of lithium therapy is clinically challenging in many patients with bipolar affective disorder because of the lack of effective therapeutic alternatives. Adequate monitoring is essential in order to identify possible complications and, thus, institute early and appropriate treatment.
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